BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25386824)

  • 1. Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents.
    Chohan TA; Qian H; Pan Y; Chen JZ
    Curr Med Chem; 2015; 22(2):237-63. PubMed ID: 25386824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
    Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
    Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.
    Tadesse S; Caldon EC; Tilley W; Wang S
    J Med Chem; 2019 May; 62(9):4233-4251. PubMed ID: 30543440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
    Sakurikar N; Thompson R; Montano R; Eastman A
    Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure.
    Jansa J; Jorda R; Škerlová J; Pachl P; Peřina M; Řezníčková E; Heger T; Gucký T; Řezáčová P; Lyčka A; Kryštof V
    Eur J Med Chem; 2021 Apr; 216():113309. PubMed ID: 33711765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
    Mou J; Chen D; Deng Y
    Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-Dependent Kinase 2 in Cellular Senescence and Cancer. A Structural and Functional Review.
    Volkart PA; Bitencourt-Ferreira G; Souto AA; de Azevedo WF
    Curr Drug Targets; 2019; 20(7):716-726. PubMed ID: 30516105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.
    Talapati SR; Nataraj V; Pothuganti M; Gore S; Ramachandra M; Antony T; More SS; Krishnamurthy NR
    Acta Crystallogr F Struct Biol Commun; 2020 Aug; 76(Pt 8):350-356. PubMed ID: 32744246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel binding pocket of cyclin-dependent kinase 2.
    Chen H; Van Duyne R; Zhang N; Kashanchi F; Zeng C
    Proteins; 2009 Jan; 74(1):122-32. PubMed ID: 18615713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CDK2 in cancer: challenges and opportunities for therapy.
    Tadesse S; Anshabo AT; Portman N; Lim E; Tilley W; Caldon CE; Wang S
    Drug Discov Today; 2020 Feb; 25(2):406-413. PubMed ID: 31839441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.
    Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I
    Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. To control or to be controlled? Dual roles of CDK2 in DNA damage and DNA damage response.
    Liu Q; Gao J; Zhao C; Guo Y; Wang S; Shen F; Xing X; Luo Y
    DNA Repair (Amst); 2020 Jan; 85():102702. PubMed ID: 31731257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.
    Deng Y; Shipps GW; Zhao L; Siddiqui MA; Popovici-Muller J; Curran PJ; Duca JS; Hruza AW; Fischmann TO; Madison VS; Zhang R; McNemar CW; Mayhood TW; Syto R; Annis A; Kirschmeier P; Lees EM; Parry DA; Windsor WT
    Bioorg Med Chem Lett; 2014 Jan; 24(1):199-203. PubMed ID: 24332088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
    Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
    Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
    Ibrahim DA; Ismail NS
    Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusion of Structure and Ligand Based Methods for Identification of Novel CDK2 Inhibitors.
    Mahajan P; Chashoo G; Gupta M; Kumar A; Singh PP; Nargotra A
    J Chem Inf Model; 2017 Aug; 57(8):1957-1969. PubMed ID: 28723151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of CDK2 and CDK5 Dual Degrader TMX-2172.
    Teng M; Jiang J; He Z; Kwiatkowski NP; Donovan KA; Mills CE; Victor C; Hatcher JM; Fischer ES; Sorger PK; Zhang T; Gray NS
    Angew Chem Int Ed Engl; 2020 Aug; 59(33):13865-13870. PubMed ID: 32415712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in Pyrazole Based Scaffold as Cyclin-dependent Kinase 2 Inhibitors for the Treatment of Cancer.
    Shaikh J; Patel K; Khan T
    Mini Rev Med Chem; 2022; 22(8):1197-1215. PubMed ID: 34711160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2.
    Li Y; Zhang J; Gao W; Zhang L; Pan Y; Zhang S; Wang Y
    Int J Mol Sci; 2015 Apr; 16(5):9314-40. PubMed ID: 25918937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
    Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
    Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.